News
Weekly selection of relevant developments across pharmaceuticals, medical devices, CRO-related innovation and the broader healthcare business landscape.
Open Serbian versionThe Wall Street Journal reported on 3 July 2026 that Takeda entered an AI drug-discovery collaboration with Insilico Medicine worth up to $600 million. The deal adds to the pattern of large pharmaceutical companies using external AI platforms to expand early-stage discovery pipelines.
Source: WSJ
In late June, the Financial Times reported that Merck KGaA agreed to acquire a life-science tools business from Bio-Techne. The transaction is relevant for the broader MedTech and diagnostics landscape because it points to continued demand for research workflow and lab infrastructure assets.
Source: Financial Times
The Wall Street Journal reported on 2 July 2026 that Peak Rock Capital acquired Asembia, a platform focused on specialty drug distribution and related services. The deal underlines how specialty pharmacy and distribution continue to attract investment as manufacturers and service providers seek closer control over patient access channels.
Source: WSJ
Associated Press reported on 3 July 2026 that the administration proposed a rule that would reduce Medicare payments to hospitals for drugs in the 340B program. The proposal matters across the healthcare business landscape because it affects hospital drug economics, reimbursement policy and the balance between providers and payers.
Source: AP
